Testosterone + Alendronate + Placebo Alendronate + Placebo Testosterone
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hypogonadism
Conditions
Hypogonadism, Osteopenia, Osteoporosis
Trial Timeline
Oct 1, 2011 → Dec 1, 2014
NCT ID
NCT01460654About Testosterone + Alendronate + Placebo Alendronate + Placebo Testosterone
Testosterone + Alendronate + Placebo Alendronate + Placebo Testosterone is a phase 2 stage product being developed by Merck for Hypogonadism. The current trial status is terminated. This product is registered under clinical trial identifier NCT01460654. Target conditions include Hypogonadism, Osteopenia, Osteoporosis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01460654 | Phase 2 | Terminated |
Competing Products
20 competing products in Hypogonadism